A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B

Summary

UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal recommended dosage of HTS to provide a basis for Phase III confirmatory clinical research.

Timeline

Start

2025-07-01

Primary completion

2027-06-30

Completion

2030-02-28

Drugs

Indications